Halozyme Therapeutics, Inc. (HALO) Report Analysis
Corporate Events
Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to Russell 2000 Growth-Defensive Index
2022-06-24 00:00:00
Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to Russell 2000 Growth-Defensive Index
Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to Russell 2000 Defensive Index
2022-06-24 00:00:00
Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to Russell 2000 Defensive Index
Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 08:00 AM
2022-06-10 00:00:00
Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 08:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Helen I. Torley, President, CEO & Director.
Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy
2022-06-07 12:30:00
Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO™ was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS).
2022-05-23 00:00:00
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million on April 12, 2022. As per the terms of the transaction, Halozyme will acquire Antares for $5.60 per share in cash. Post deal completion, Antares Pharma shall be a wholly owned subsidiary of Halozyme. Halozyme intends to finance the transaction using existing cash on hand and new sources of debt. Halozyme Therapeutics, Inc. has received an Amended and Restated Commitment Letter dated as of April 28, 2022, pursuant to which Bank of America, N.A., BofA Securities, Inc., Wells Fargo Bank and Wells Fargo Securities, LLC have committed to provide, subject to the terms and conditions of the Amended and Restated Debt Commitment Letter, to Parent a $375 million senior secured term loan. Halozyme shall acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price. Antares Pharma shall pay a termination fee of $33 million to Halozyme. Helen Torley will be the Chief Executive Officer of the combined company. The transaction was unanimously approved by both the Halozyme and Antares Boards of Directors. The tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Antares’ outstanding shares of common stock, the expiration or termination of the HSR waiting period. The tender offer is subject to minimum shares validly tendered and not validly withdrawn represent one more than 50% of the total number of Shares outstanding. As of April 26, 2022, Halozyme commenced the tender offer. The transaction is subject to the satisfaction of customary closing conditions and applicable regulatory approvals. On April 27, 2022, a purported Antares Pharma, Inc. stockholder filed a complaint against Antares Pharma, Inc. and each member of Antares Pharma, Inc. Board in the United States District Court for the Southern District of New York. On April 30, 2022, a purported Antares Pharma, Inc. stockholder filed a complaint against Antares Pharma, Inc. and each member of Antares Pharma, Inc. Board in the United States District Court for the Eastern District of New York. As of May 12, 2022, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to the transaction, has expired. The transaction is expected to close in the first half of 2022. As of April 26, 2022, the tender offer is scheduled to expire on May 23, 2022. The transaction is expected to be immediately accretive to Halozyme’s 2022 revenue and non-GAAP earnings. BofA Securities and Wells Fargo Securities LLC are acting as financial advisors to Halozyme and Michael J. Aiello and Sachin Kohli of Weil, Gotshal & Manges LLP is acting as legal advisor. Jefferies LLC is acting as financial advisor and fairness opinion provider to Antares and Graham Robinson and Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal advisor. Roy Tannenbaum and Philip Richter of Fried Frank acted as counsel to BofA Securities. Equiniti Trust Company is depositary and the transfer agent of Antares. D.F. King & Co., Inc. is acting as information agent of Antares. Cahill Gordon & Reindel LLP acted as legal counsel the lender in the transaction. Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS) on May 23, 2022. In connection with the merger, all Antares shares not validly tendered in the tender offer have been converted into the right to receive the same $5.60 per share in cash. As of May 24, 2022, Antares common stock will cease to be traded on the NASDAQ Global Select Stock Market. The minimum tender condition and all of the other conditions to the offer have been satisfied. As of May 24, 2022, Antares Pharma deregistration of unsold securities.
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022
2022-05-10 20:01:00
Halozyme Therapeutics, Inc. reiterating earnings guidance for the year 2022. For the year, the company expects net revenue to be in the range of $530 million to $560 million, GAAP operating income to be in the range of $350 million to $380 million, GAAP net income to be in the range of $270 million to $295 million and GAAP diluted EPS to be in the range of $1.90 to $2.05.
Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022
2022-05-03 18:20:00
Halozyme Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022
Halozyme Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
2022-05-03 18:20:00
Halozyme Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
Antares Pharma, Inc., Halozyme Therapeutics, Inc. - M&A Call
2022-04-13 10:00:00
Halozyme Therapeutics, Inc. to acquire Antares Pharma, Inc
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million.
2022-04-13 00:00:00
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million on April 12, 2022. As per the terms of the transaction, Halozyme will acquire Antares for $5.60 per share in cash. Post deal completion, Antares Pharma shall be a wholly owned subsidiary of Halozyme. Halozyme intends to finance the transaction using existing cash on hand and new sources of debt. Halozyme Therapeutics, Inc. has received an Amended and Restated Commitment Letter dated as of April 28, 2022, pursuant to which Bank of America, N.A., BofA Securities, Inc., Wells Fargo Bank and Wells Fargo Securities, LLC have committed to provide, subject to the terms and conditions of the Amended and Restated Debt Commitment Letter, to Parent a $375 million senior secured term loan. Halozyme shall acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price. Antares Pharma shall pay a termination fee of $33 million to Halozyme. Helen Torley will be the Chief Executive Officer of the combined company. The transaction was unanimously approved by both the Halozyme and Antares Boards of Directors. The tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Antares’ outstanding shares of common stock, the expiration or termination of the HSR waiting period. The tender offer is subject to minimum shares validly tendered and not validly withdrawn represent one more than 50% of the total number of Shares outstanding. As of April 26, 2022, Halozyme commenced the tender offer. The transaction is subject to the satisfaction of customary closing conditions and applicable regulatory approvals. On April 27, 2022, a purported Antares Pharma, Inc. stockholder filed a complaint against Antares Pharma, Inc. and each member of Antares Pharma, Inc. Board in the United States District Court for the Southern District of New York. On April 30, 2022, a purported Antares Pharma, Inc. stockholder filed a complaint against Antares Pharma, Inc. and each member of Antares Pharma, Inc. Board in the United States District Court for the Eastern District of New York. As of May 12, 2022, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to the transaction, has expired. The transaction is expected to close in the first half of 2022. As of April 26, 2022, the tender offer is scheduled to expire on May 23, 2022. The transaction is expected to be immediately accretive to Halozyme’s 2022 revenue and non-GAAP earnings. BofA Securities and Wells Fargo Securities LLC are acting as financial advisors to Halozyme and Michael J. Aiello and Sachin Kohli of Weil, Gotshal & Manges LLP is acting as legal advisor. Jefferies LLC is acting as financial advisor and fairness opinion provider to Antares and Graham Robinson and Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal advisor. Roy Tannenbaum and Philip Richter of Fried Frank acted as counsel to BofA Securities. Equiniti Trust Company is depositary and the transfer agent of Antares. D.F. King & Co., Inc. is acting as information agent of Antares. Cahill Gordon & Reindel LLP acted as legal counsel the lender in the transaction.
Halozyme Therapeutics, Inc. - Shareholder/Analyst Call
2022-03-25 20:31:00
Annual Meeting of Stockholders
Halozyme Therapeutics, Inc., Annual General Meeting, May 05, 2022
2022-03-25 20:31:00
Halozyme Therapeutics, Inc., Annual General Meeting, May 05, 2022, at 08:00 Pacific Standard Time. Agenda: To consider election of three Class III director nominees named in this Proxy Statement to the Board of Directors, each to serve a three-year term and until their respective successors are elected and qualified; to consider approval of a non-binding advisory resolution approving the compensation of Named Executive Officers; and to consider ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022.
Tranche Update on Halozyme Therapeutics, Inc. (NasdaqGS:HALO)'s Equity Buyback Plan announced on November 4, 2019.
2022-02-22 16:22:00
From October 1, 2021 to October 31, 2021, the company has repurchased 273,210 shares, representing 0.19% for $9.5 million. With this, the company has completed the repurchase of 22,250,346 shares, representing 15.7% for $550 million under the buyback announced on November 4, 2019.
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Halozyme Therapeutics, Inc. Announces Executive Changes
2022-02-03 21:13:00
On February 2, 2022, Halozyme Therapeutics, Inc. announced that Elaine Sun is stepping down from her position as senior vice president of the company, effective immediately, to pursue another opportunity. On February 2, 2022, Nicole LaBrosse was appointed as senior vice president of the company, effective immediately. Ms. LaBrosse has served as the company’s vice president, finance and accounting since January 2020.
Halozyme Therapeutics, Inc. Announces Change of Chief Financial Officer
2022-02-02 21:43:00
Halozyme Therapeutics, Inc. announced that Nicole LaBrosse has been promoted to the position of chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity. Ms. LaBrosse joined Halozyme in 2015 and has since held roles of growing responsibility within the Company. Most recently, Ms. LaBrosse served as Halozyme's vice president, finance and accounting since 2020.
Halozyme Therapeutics, Inc. Announces Executive Changes
2021-12-13 21:05:00
Halozyme Therapeutics, Inc. announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue another opportunity. Mr. Snyder brings almost thirty years of legal and business experience to Halozyme. Over his career he has led and played key roles in a broad range of intellectual property, licensing, regulatory, anti-trust and litigation matters. Most recently Mr. Snyder served as senior vice president, deputy general counsel, litigation for Qualcomm Incorporated, a large, public, multinational wireless technology company with more than 40,000 employees.
Halozyme Therapeutics, Inc. Amends Company’s Bylaws
2021-12-10 21:08:00
On December 8, 2021, the Board of Directors of Halozyme Therapeutics, Inc. amended the Company’s Bylaws to adopt a majority voting standard for uncontested elections of directors. As revised, the Bylaws provide that in any election of one or more directors at a meeting of stockholders at which a quorum is present other than in a contested election, directors shall be elected by the vote of a majority of the votes cast by the stockholders and only in the case of any contested election, directors shall be elected by a plurality of votes cast by stockholders. The Company’s Bylaws were also amended to supplement various disclosure requirements in connection with notices given to the Company containing a nomination of any individual for election as director to the Board and to clarify eligibility and disclosure requirements for such nominees to be elected to the Board. The enhanced disclosures include information and/or representations regarding such matters as independence, compliance with policies applicable to other directors, stock ownership issues, voting commitments and compensation arrangements.
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares.
2021-12-09 21:01:00
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its outstanding common stock. The Company plans to fund repurchases from its existing cash balance. The repurchase program is valid for 3 years.
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.
2021-12-09 00:00:00
The Board of Directors of Halozyme Therapeutics, Inc. has authorized a buyback plan on December 9, 2021.
Halozyme Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
Halozyme Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.
Halozyme Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-18 14:00:00
Halozyme Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Elaine D. Sun, Senior VP & CFO.
Halozyme Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 03:55 PM
2021-11-18 14:00:00
Halozyme Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 03:55 PM. Speakers: Helen I. Torley, President, CEO & Director.
Halozyme Therapeutics, Inc. Updates Earnings Outlook for the Full Year 2021
2021-11-02 20:04:00
Halozyme Therapeutics, Inc. updated earnings outlook for the full year 2021. For the period, the company expects Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-over-year growth of 61%-66%; GAAP Operating Income of $265 million to $280 million, increased from prior guidance of $260 million to $280 million, representing year-over-year growth of 84%-94%; GAAP Net Income of $380 million to $395 million, up from prior guidance of $235 million to $255 million due to the income tax benefit recorded in third quarter 2021; GAAP Diluted Earnings per Share of $2.60 to $2.70, up from prior guidance of $1.55 to $1.70 due to the income tax benefit recorded in third quarter 2021.
Tranche Update on Halozyme Therapeutics, Inc. (NasdaqGS:HALO)'s Equity Buyback Plan announced on November 4, 2019.
2021-11-02 16:10:00
From July 1, 2021 to September 30, 2021, the company has repurchased 1,562,613 shares, representing 1.1% for $64.68 million. With this, the company has completed the repurchase of 21,977,136 shares, representing 15.51% for $540.5 million under the buyback announced on November 4, 2019.
Halozyme Therapeutics, Inc.'s Equity Buyback announced on November 4, 2019, has closed with 22,250,346 shares, representing 15.7% for $550 million.
2021-10-31 00:00:00
The company closed its plan in October 2021.
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
Halozyme Therapeutics, Inc. Presents at Berenberg US CEO Conference 2021, Nov-09-2021
2021-10-23 03:37:00
Halozyme Therapeutics, Inc. Presents at Berenberg US CEO Conference 2021, Nov-09-2021 .
Halozyme Therapeutics, Inc., Q3 2021 Earnings Call, Nov 02, 2021
2021-10-19 20:05:00
Halozyme Therapeutics, Inc., Q3 2021 Earnings Call, Nov 02, 2021
Halozyme Therapeutics, Inc. to Report Q3, 2021 Results on Nov 02, 2021
2021-10-19 20:05:00
Halozyme Therapeutics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021
Halozyme Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 01:20 PM
2021-09-15 20:05:00
Halozyme Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 01:20 PM. Venue: New York, United States. Speakers: Elaine D. Sun, Senior VP & CFO.
Joh. Berenberg, Gossler & Co. KG, Berenberg US CEO Conference 2021, Nov 09, 2021 through Nov 10, 2021
2021-09-07 11:00:00
Joh. Berenberg, Gossler & Co. KG, Berenberg US CEO Conference 2021, Nov 09, 2021 through Nov 10, 2021.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Year 2021
2021-08-09 20:03:00
Halozyme Therapeutics, Inc. raised earnings guidance for the year 2021. Based on the recent signing of a new collaboration and license agreement and strong year-to-date results as well as the latest information from collaboration partners and planned expenditures for the year, the Company is raising guidance for 2021 and now expects revenues of $425 million to $445 million, representing year-over-year growth of 59%-66%, and up from prior guidance of $375 to $395 million. GAAP Operating Income of $260 million to $280 million, representing year-over-year growth of 80%-94%. GAAP Net Income of $235 million to $255 million, representing year-over-year growth of 82%-98%. GAAP Diluted Earnings per Share of $1.55 to $1.70, representing year-over-year growth of 70%-86%, up from prior guidance of $1.25 to $1.40.
Tranche Update on Halozyme Therapeutics, Inc. (NasdaqGS:HALO)'s Equity Buyback Plan announced on November 4, 2019.
2021-08-09 16:07:00
From April 1, 2021 to June 30, 2021, the company has repurchased 1,037,547 shares, representing 0.72% for $48.82 million. With this, the company has completed the repurchase of 20,414,523 shares, representing 14.41% for $475.81 million under the buyback announced on November 4, 2019.
Halozyme Therapeutics, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 03:30 PM
2021-07-30 12:00:00
Halozyme Therapeutics, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 03:30 PM. Speakers: Elaine D. Sun, Senior VP & CFO.
Halozyme Therapeutics, Inc., Q2 2021 Earnings Call, Aug 09, 2021
2021-07-27 20:05:00
Halozyme Therapeutics, Inc., Q2 2021 Earnings Call, Aug 09, 2021
Halozyme Therapeutics, Inc. to Report Q2, 2021 Results on Aug 09, 2021
2021-07-27 20:05:00
Halozyme Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021
Halozyme Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 10:40 AM
2021-07-22 14:24:00
Halozyme Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 10:40 AM. Speakers: Albert S. Kildani, Vice President of Investor Relations & Corporate Communications, Helen I. Torley, President, CEO & Director.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
Fundamental Summary
At a high level, the metrics from Halozyme Therapeutics's Q1 financial report release provided many positive indicators. Their growth, value, and income factors indicate a well-executed and balanced strategy, which is generating exciting growth. This relative strength should allow Halozyme Therapeutics to continue to perform well even in a tough market. Therefore, they earned a total score of 81 out of 100 and a BUY recommendation.
Halozyme Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 117.28 million compared to USD 89.02 million a year ago. Net income was USD 60.11 million compared to USD 27.9 million a year ago. Basic earnings per share from continuing operations was USD 0.44 compared to USD 0.2 a year ago. Diluted earnings per share from continuing operations was USD 0.43 compared to USD 0.19 a year ago.
Business Description
Halozyme Therapeutics operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics was founded in 1998 and is based in San Diego, California.
Sector Overview
Halozyme Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Halozyme Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 265.3 | 14.6% | 85 | |
| Net Cashflow | -381.6 | -1216.6% | 83 | |
| Capital Expenditure | -1.7 | -15.1% | 52 | |
| Asset Turnover | 0.4 | -15.8% | 49 | |
| Free Cashflow | 2.0 | -3.5% | 66 |
* All values are TTM
The below chart reflects Halozyme Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Halozyme Therapeutics's peer average final assessment score stands on 64.0, Halozyme Therapeutics's score is 81.
- HALO
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Halozyme Therapeutics's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Halozyme Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.
5D MA
46.48
50D MA
43.49
200D MA
38.81
MACD
0.77
RSI
38.9
STOCH
68.02
Balance Sheet Analysis
Overall, Halozyme Therapeutics's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Halozyme Therapeutics publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 23.2 and represents a -17.4% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. The company's book value factors component, therefore, received a grade of 85. Also, Halozyme Therapeutics did a great job related to cash and cash equivalents this period, which stood at 117.8, representing a -0.7% change from the previous filing. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its cash and cash equivalents movement earned a score of 72. At the same time, one critical balance sheet metric, Liabilities, was notably weak. Halozyme Therapeutics's liabilities stood at 902.0 in the current filing, which represents a -0.6% change from the previous report. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Therefore, we rated their liabilities movement with a score of 59. Therefore, its balance sheet earned a grade of 74.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 1,162.2 | 5.2% | 68 |
| Liabilities | 902.0 | -0.6% | 59 |
| Price to Book | 23.2 | -17.4% | 85 |
| Cash & Equivalents | 117.8 | -0.7% | 72 |
| Equity | 260.3 | 32.1% | 65 |
The below chart describes Halozyme Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Halozyme Therapeutics received a balance sheet score of 74, the average of its peers stands on 63.0.
- HALO
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 14 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 15 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 17 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 19 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 22 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Halozyme Therapeutics appears likely to maintain its strong income statement metrics and momentum going forward. In this filing, Halozyme Therapeutics reported a return on equity (ROE) ratio of 265.3, which represents a change of 14.6%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 85. Also, Halozyme Therapeutics's management was effective in improving its EBIDTA, which now sits at 304.3 and represents a 8.9% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 84. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Halozyme Therapeutics management did an underwhelming job managing revenue efficiency this past period. Halozyme Therapeutics's revenue efficiency is 471.6 according to the metrics in the current filing, which represents a 6.4% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. As a result, their revenue efficiency earned a score of 53. Therefore, it received a score of 82.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 304.3 | 8.9% | 84 |
| Total Revenues | 471.6 | 6.4% | 53 |
| Return on Equity | 265.3 | 14.6% | 85 |
The below chart describes Halozyme Therapeutics's performance as reflected on its income statement with respect to its peers. While Halozyme Therapeutics received a income statement score of 82 , the average of its peers stands on 63.0.
- HALO
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 14 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 15 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 17 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 22 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Net Cash Flow and Free Cash flow stand out as the most significant drivers of Halozyme Therapeutics's cash flow's strength. Halozyme Therapeutics's strong net cash flow numbers, which were -381.6 in this filing, showed a -1216.6% change from the last period. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 83. Also, Halozyme Therapeutics did a great job related to free cash flow this period, which stood at 2.0, representing a -3.5% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. The company's free cash flow movement, therefore, received a grade of 66. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. Halozyme Therapeutics's asset turnover metrics were concerning and highlighted potential issues management is having effectively turning assets into sales efficiently. At filing, their asset turnover metrics were 0.4, representing a -15.8% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Therefore, their asset turnover movement earned a score of 49. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 75.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -381.6 | -1216.6% | 83 |
| Capital Expenditure | -1.7 | -15.1% | 52 |
| Asset Turnover | 0.4 | -15.8% | 49 |
| Free Cashflow | 2.0 | -3.5% | 66 |
The below chart describes Halozyme Therapeutics's performance as reflected on its cash flow with respect to its peers. While Halozyme Therapeutics received a cash flow score of 75, the average of its peers stands on 71.0.
- HALO
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 14 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 15 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 17 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 22 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.